Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA.
J Crit Care. 2011 Jun;26(3):328.e1-8. doi: 10.1016/j.jcrc.2010.08.018. Epub 2010 Oct 30.
Although pulse pressure variation (PPV) and stroke volume variation (SVV) during mechanical ventilation have been shown to predict preload responsiveness, the effect of vasoactive therapy on PPV and SVV is unknown.
Pulse pressure variation and SVV were measured continuously in 15 cardiac surgery patients for the first 4 postoperative hours. Pulse pressure variation was directly measured from the arterial pressure waveform, and both PPV and SVV were also calculated by LiDCO Plus (LiDCO Ltd, Cambridge, United Kingdom) before and after volume challenges or changes in vasoactive drug infusions done to sustain cardiovascular stability.
Seventy-one paired events were studied (38 vasodilator, 10 vasoconstrictor, 14 inotropes, and 9 volume challenges). The difference between the measured and LiDCO-calculated PPV was 1% ± 7% (1.96 SD, 95% confidence interval, r(2) = 0.8). Volume challenge decreased both PPV and SVV (15% to 10%, P < .05 and 13% to 9%, P = .09, respectively). Vasodilator therapy increased PPV and SVV (13% to 17% and 9% to 15%, respectively, P < .001), whereas increasing inotropes or vasoconstrictors did not alter PPV or SVV. The PPV/SVV ratio was unaffected by treatments.
Volume loading decreased PPV and SVV; and vasodilators increased both, consistent with their known cardiovascular effects. Thus, SVV and PPV can be used to drive fluid resuscitation algorithms in the setting of changing vasoactive drug therapy.
虽然机械通气期间的脉压变化(PPV)和每搏量变化(SVV)已被证明可预测前负荷反应性,但血管活性药物治疗对 PPV 和 SVV 的影响尚不清楚。
在心脏手术后的头 4 个小时内,连续测量 15 例心脏手术患者的脉压变化和 SVV。直接从动脉压力波形测量脉压变化,并且在容量挑战或改变血管活性药物输注以维持心血管稳定性之前和之后,通过 LiDCO Plus(LiDCO Ltd,英国剑桥)计算 PPV 和 SVV。
研究了 71 对事件(38 个血管扩张剂,10 个血管收缩剂,14 个正性肌力药和 9 个容量挑战)。测量的 PPV 与 LiDCO 计算的 PPV 之间的差异为 1%±7%(1.96 标准差,95%置信区间,r(2) = 0.8)。容量挑战降低了 PPV 和 SVV(分别降低 15%至 10%,P <.05 和 13%至 9%,P =.09)。血管扩张剂治疗增加了 PPV 和 SVV(分别增加 13%至 17%和 9%至 15%,P <.001),而增加正性肌力药或血管收缩剂则不改变 PPV 或 SVV。PPV/SVV 比值不受治疗影响。
容量负荷降低了 PPV 和 SVV;血管扩张剂增加了两者,这与它们已知的心血管作用一致。因此,SVV 和 PPV 可用于在改变血管活性药物治疗的情况下驱动液体复苏算法。